Related by context. All words. (Click for frequent words.) 84 preclinical 73 preclinical models 72 Preclinical studies 70 preclinical efficacy 70 nonclinical studies 69 clinical trials 68 vitro studies 67 oral prodrug 67 PXD# 67 JAK inhibitor 67 Phase Ib 66 RDEA# 66 Homspera 66 Phase 2a trial 66 TOCOSOL Paclitaxel 66 INCB# [001] 66 ganetespib 66 PSN# [002] 65 INGN 65 GRN#L 65 Preclinical 65 Phase IIa clinical trials 65 Phase Ib clinical 65 HspE7 65 Phase IIa 65 vitro experiments 65 ANAVEX #-# [003] 65 vivo efficacy 65 Phase IIa trial 65 Factor VIIa 65 NGX# 65 OXi# 65 Phase 2a clinical 65 vivo 65 TKM ApoB 64 preclinically 64 Phase 1b trial 64 Phase IIa clinical 64 Sym# 64 huC# DM4 64 IND enabling 64 AVN# [001] 64 Phase Ib study 64 PEG SN# 64 Phase III clinical trials 64 IDX# 64 cannabinor 64 GLP toxicology studies 64 PS# [001] 64 JAK2 inhibitor 64 pharmacokinetic 63 Triolex 63 ALN TTR# 63 Phase 2a 63 iSONEP 63 HGS ETR1 63 ENMD # 63 phase IIa clinical 63 GAP #B# 63 Phase III trials 63 Phase IIb trials 63 investigational humanized monoclonal antibody 63 TRIOLEX 63 small molecule inhibitors 63 tolerability profile 63 orally bioavailable 63 neuroprotective 63 CA4P 63 immunomodulatory 63 teduglutide 63 Phase IIb 63 HQK 63 trodusquemine 63 DXL# 63 systemically administered 62 Azixa 62 iroxanadine 62 mertansine 62 PRT# 62 clinical trial 62 bavituximab 62 MGCD# [001] 62 BCX# 62 nanoviricides 62 BioVant 62 LY# [003] 62 JAK1 62 Bendavia 62 CORT # 62 pharmacokinetic studies 62 Valortim 62 histone deacetylase HDAC inhibitor 62 ISIS # 62 Sphingomab 62 TELINTRA 62 preclinical toxicology 62 phase IIa 62 MEK inhibitor 62 HGS# 62 pharmacodynamic properties 62 Phase 2b study 62 favorable pharmacokinetic profile 62 milatuzumab 62 LEP ETU 62 phase IIb clinical 62 ImmunoVEX HSV2 62 AEZS 62 antitumor activity 62 Panzem 62 RGB # 61 Phase IIb clinical trials 61 HCV protease 61 AQ4N 61 Phase 1b 61 APOPTONE 61 CR# vcMMAE 61 PDE4 inhibitor 61 anti leukemic 61 PLK1 SNALP 61 Tarvacin TM 61 CGEN # 61 anti angiogenic 61 midstage trials 61 antiviral activity 61 MLN# 61 Phase 1b clinical 61 neuroprotective properties 61 immune modulation 61 vidofludimus 61 Serdaxin 61 Phase IIb clinical 61 oral bioavailability 61 Phase Ib clinical trials 61 tolerability 61 #D#C# 61 Phase III clinical 61 alagebrium 61 CRLX# 61 PEG Interferon lambda 61 AP# [003] 61 SRT# [003] 61 APD# 61 Azedra 61 obatoclax 61 Synavive 61 pradefovir 61 elacytarabine 61 investigational compound 61 ANG# 61 OncoVEX GM CSF 61 Carfilzomib 61 AEG# 61 CCX# 61 axitinib 61 Phase 2b clinical 61 ASONEP 61 Hsp# inhibitor 61 novel peptide 61 MGCD# [002] 61 KRN# 61 CYT# 61 #ME# 61 CUDC 61 fosbretabulin 61 polymerase inhibitor 61 VQD 61 Panzem R 61 SNALP technology 61 AEOL # 61 protein kinase inhibitor 61 PEGPH# 60 CEQ# 60 enzastaurin 60 dacetuzumab 60 PCK# 60 Preclinical studies suggest 60 Debio 60 IND submission 60 NEUMUNE 60 ADX# 60 triphendiol 60 Tarvacin 60 XmAb# 60 SERMs 60 telomerase inhibitor drug 60 selective inhibition 60 Nasulin 60 small molecule 60 tezampanel 60 bafetinib 60 HCV protease inhibitor 60 SARMs 60 OMP #M# 60 depsipeptide 60 CD# CEA 60 Valortim R 60 QLT# 60 deforolimus 60 angiogenesis inhibitor 60 voreloxin 60 Phase IIa trials 60 Hsp# inhibitors 60 vismodegib 60 phase 2a 60 solithromycin 60 potent inhibitor 60 ProSavin 60 eltrombopag 60 Symadex 60 monoclonal antibody 60 JAK inhibitors 60 elotuzumab 60 ocular formulation 60 CBLC# 60 NexACT 60 vivo validation 60 phase IIb 60 TB4 60 HuMax CD# 60 SIRT1 activators 60 investigational drug 60 CCR2 60 talactoferrin 60 antitumor 60 OvaRex R 60 HGS ETR2 60 next generation URAT1 60 ApoB SNALP 60 pharmacodynamic PD 60 adenoviral 60 XL# [003] 60 IMGN# 60 PRX # 60 novel anticancer 60 OHR/AVR# 60 HCV nucleotide polymerase inhibitor 60 VEGF Trap 60 squalamine 60 Androxal TM 60 ATL# [001] 60 BNC# 60 pharmacokinetic properties 60 Phase IIb trial 60 Marqibo 60 R#/MEM # 60 BiTE antibody 60 confirmatory Phase III 60 Onconase 59 small molecule defensin 59 XL# XL# 59 AzaSite Plus 59 ALN RSV# 59 GALNS 59 perifosine 59 Nanobody 59 Interferon alpha 59 HCV polymerase inhibitor 59 histone deacetylase inhibitor 59 preclinical pharmacokinetic 59 ALN PCS 59 DOS# 59 efficacy 59 pharmacokinetic profile 59 MultiStem 59 CoFactor 59 antitumor effects 59 rBChE 59 Phase 2b trial 59 eniluracil 59 ZFP Therapeutic 59 HDAC inhibitors 59 MB# [004] 59 GGF2 59 alvespimycin 59 PRTX 59 ALN TTR 59 immunogenicity 59 RNAi therapeutic 59 CCR5 antagonist 59 tolerability profiles 59 MEK inhibitors 59 GSK# [002] 59 adipiplon 59 selective androgen receptor modulator 59 ALN VSP 59 Perifosine 59 HDAC inhibitor 59 Archexin 59 ALTU 59 otelixizumab 59 HuLuc# 59 CG# [003] 59 multi kinase inhibitor 59 RhuDex ® 59 MEK inhibitor RDEA# 59 vascular disrupting agent 59 picoplatin 59 PD LID 59 entinostat 59 Prodarsan ® 59 ARRY 59 Phase #/#a 59 synthetic retinoid 59 MAXY G# 59 dirucotide 59 Xanafide 59 JAK3 59 Phase 2b clinical trials 59 ProMune 59 Hedgehog pathway 59 Tβ4 59 OncoVEX 59 antisense drug 59 AZX# 59 SAR# [004] 59 GRNCM1 59 Phenserine 59 stable nucleic acid 59 CB2 selective receptor agonist 59 MDV# 59 xenograft models 59 retapamulin 59 MBP# [001] 59 non nucleoside HCV 59 Zybrestat 59 proteasome inhibitor 59 riociguat 59 disease modifying 59 HuCNS SC cells 59 orally administered inhibitor 59 TG# [003] 59 panitumumab Vectibix 59 anti proliferative 59 rNAPc2 59 Chrysalin 59 vosaroxin 59 XmAb ® 59 TRO# 59 cancer immunotherapies 59 ProLindac 58 Zoraxel 58 phase IIb study 58 Phase 2a clinical trials 58 anticancer activity 58 Angiolix 58 PNP inhibitor 58 isoform selective 58 Tyrima 58 anticancer agent 58 Traficet EN 58 huN# DM1 58 Chemophase 58 hematological cancers 58 Amplimexon 58 forodesine 58 elesclomol 58 ocrelizumab 58 Phase Ia 58 Phase 1b clinical trials 58 NEUGENE antisense 58 tanespimycin 58 tivozanib 58 orally dosed 58 KNS # 58 JAK2 inhibitors 58 velafermin belinostat 58 pharmacokinetic PK 58 BRAF inhibitor 58 MAP# 58 midstage clinical trials 58 THR beta agonist 58 Aurora kinase inhibitor 58 ESBA# 58 Apoptone 58 varespladib 58 Cintredekin Besudotox 58 Phase 1a clinical 58 Bicifadine 58 Phase #b/#a trial 58 Kahalalide F 58 bortezomib 58 NEUGENE 58 liposomal formulation 58 atacicept 58 SCH # 58 siRNA 58 investigational monoclonal antibody 58 induce apoptosis 58 oral gallium 58 pharmacodynamic profile 58 CCR9 antagonist 58 pharmacological chaperone 58 humanized monoclonal antibody 58 anti fibrotic 58 PEG PAL 58 IAP inhibitors 58 telomerase therapeutic 58 CRx 58 TACI Ig 58 pan HDAC inhibitor 58 PBT2 58 REP# 58 celgosivir 58 Posiphen 58 humanized antibodies 58 ruxolitinib 58 Trofex 58 L DOS# 58 AEGR 58 RNAi therapeutic targeting 58 Vitaxin 58 Exelixis compounds 58 HuMax EGFr 58 Enzastaurin 58 virus HCV protease inhibitor 58 pharmacodynamics 58 S/GSK# 58 Fx #A 58 Protexia ® 58 imetelstat 58 Menerba 58 kinase inhibitor 58 AKT inhibitor 58 IMA# 58 VA# [002] 58 pharmacodynamic 58 oritavancin 58 Pimavanserin 58 AMD# [003] 58 volociximab 58 Valortim ® 58 pertuzumab 58 Exherin TM 58 radiation sensitizer 58 Plicera 58 Alocrest 58 AACR NCI EORTC 58 Phase 1a 58 olaparib 58 novel VDA molecule 58 Cethromycin 58 GDIR 58 vascular disrupting agents 58 IL# PE 58 omecamtiv mecarbil 58 NP2 Enkephalin 58 potent antitumor activity 58 antiangiogenic activity 58 HSP# inhibitor 58 pralatrexate 58 PROSTVAC TM 58 indibulin 58 TELCYTA 58 mGluR2 NAM 58 Nanobody ® 58 FluCide 58 FOLOTYN ® 58 Pharmacokinetic studies 58 immunotherapeutic 58 pomalidomide 58 siRNA therapeutics 58 PI3K inhibitor 57 Asentar 57 cMET 57 nalbuphine ER 57 tafamidis 57 lomitapide 57 PROMACTA 57 GSK # 57 Neuradiab 57 vivo preclinical 57 PLX cells 57 biodistribution 57 resolvin 57 rFIXFc 57 bevasiranib 57 Reolysin 57 DR Cysteamine 57 pharmacokinetics 57 sorafenib Nexavar 57 mitotic kinesins 57 neratinib 57 Relivar 57 peripherally acting 57 IAP inhibitor 57 CaPre TM 57 davunetide intranasal AL 57 TLR8 57 Omacetaxine 57 RG# [001] 57 ostarine 57 torezolid phosphate 57 personalized immunotherapy 57 TLR8 agonist 57 MAXY alpha 57 p# inhibitor 57 hypoxia activated prodrug 57 Vaxfectin 57 PEP# [003] 57 Curaxin CBLC# 57 humanized anti 57 urocortin 2 57 lintuzumab 57 investigational compounds 57 HCV protease inhibitors 57 clinical 57 oncolytic virus 57 Kevetrin 57 Anthim 57 NeuroVax TM 57 BiTE antibodies 57 PF # [001] 57 trastuzumab Herceptin R 57 FK# 57 brostallicin 57 AMPK activators 57 Zerenex 57 MyVax R 57 Dacogen injection 57 GLPG# 57 ISTODAX 57 midstage clinical 57 nitazoxanide 57 PSMA ADC 57 anti VEGF 57 LE SN# 57 GRN# 57 mapatumumab 57 Lpathomab 57 epothilones 57 rindopepimut 57 teriflunomide 57 targeting CD# 57 preclinical compounds 57 polymerase inhibitors 57 Phase #b/#a 57 Cethrin 57 proteasome inhibitors 57 RH1 57 ALN HTT 57 GLYX 57 p# inhibitors 57 Viprinex 57 Phase 2b 57 Thiovir 57 tremelimumab 57 novel histone deacetylase 57 PEGylated 57 phase IIb trial 57 ELND# 57 MAGE A3 ASCI 57 KSP inhibitors 57 selective modulator 57 Tß4 57 BAY #-# 57 Tamibarotene 57 Trofex TM 57 velafermin 57 Mipomersen 57 Radilex 57 brivaracetam 57 HDL Mimetic Peptide 57 NTx TM -# 57 reslizumab 57 decitabine 57 RAV# 57 TLR7 57 metaglidasen 57 hGH CTP 57 INT# [002] 57 Hedgehog signaling pathway 57 GRNVAC1 57 Guanilib 57 cobiprostone 57 Genasense ® oblimersen 57 Tarceva TM 57 TRV# [001] 57 MOZOBIL 57 Aurora kinase inhibitors 57 Adentri 57 inhibitor RG# 57 ulimorelin 57 H#N# VLP vaccine 57 YONDELIS 57 Pazopanib 57 allosteric modulator 57 PI3K delta 57 Cloretazine ® 57 EDEMA3 trial 57 CK # 57 NKTR 57 clinical pharmacology studies 57 targeted radiotherapeutic 57 TREANDA 57 bicifadine 57 mouse xenograft models 57 methylnaltrexone 57 Tarvacin Anti Viral 57 bortezomib Velcade 57 CYT# potent vascular disrupting 57 antisense inhibition 57 AZD# 57 anti amnesic 56 CD# antibody [001] 56 Zalypsis 56 ZYBRESTAT 56 synthetic peptide 56 Virulizin R 56 daclizumab 56 bevirimat 56 erlotinib Tarceva ® 56 Squalamine 56 Ocrelizumab 56 OMNARIS HFA 56 Allovectin 7 R 56 aurora kinase 56 HDAC Inhibitor 56 belinostat 56 Hsp# Inhibitor 56 Cloretazine R VNP#M 56 prokinetic agent 56 Protexia R 56 Anticalin R 56 MORAb 56 Tovaxin 56 XL# anticancer compounds 56 anticancer agents 56 Fibrillex TM 56 immune modulatory 56 Hedgehog antagonist 56 TRX1 56 isavuconazole 56 HuMax CD4 56 Amigal 56 PDE4 inhibitors 56 AAG geldanamycin analog 56 CRD5 56 TYZEKA 56 phase Ib 56 exon skipping 56 flavopiridol 56 NovaBay Aganocide compounds 56 multitargeted 56 RNAi therapeutic targeting PCSK9 56 Personalized Immunotherapy 56 dose escalation study 56 mAb 56 orally administered 56 Atiprimod 56 CD# monoclonal antibody 56 LY# [002] 56 TLK# 56 small molecule tyrosine 56 mTOR inhibitors 56 nanoviricide 56 COPREXA 56 nanopharmaceutical 56 nicotinic alpha 7 56 docetaxel Taxotere R 56 antisense 56 Multimeric 56 Aplidin 56 INCB# [002] 56 fibrotic disease 56 bendamustine 56 antiviral efficacy 56 therapeutic monoclonal antibody 56 ANAVEX #-# [001] 56 carfilzomib 56 eprotirome 56 Vilazodone 56 Onalta 56 telomerase inhibitor 56 potent anticancer 56 LNP formulations 56 cysteamine 56 encapsulates siRNAs 56 AVE# 56 seliciclib CYC# 56 targeting PCSK9 56 Actilon 56 lenalidomide Revlimid R 56 menadione 56 omega interferon 56 HCD# [002] 56 ongoing Phase 1b 56 generation URAT1 inhibitor 56 AeroLEF TM 56 Vidofludimus 56 HE# [002] 56 bremelanotide 56 cilengitide 56 tranilast 56 ritonavir boosting 56 IRX 2 56 KB# [002] 56 NVA# 56 Revimmune 56 immune stimulatory 56 Tezampanel 56 nucleotide analog 56 Novolimus 56 sulodexide 56 SGS# 56 Viprovex TM 56 investigational 56 siRNA therapeutic 56 immunomodulator 56 HDACi 56 delafloxacin 56 diabetic neuropathic pain 56 mGluR5 negative 56 Alpharadin 56 CIMZIA ™ 56 Hsp# inhibition 56 ARIKACE ™ 56 PROCHYMAL 56 Proxinium TM 56 Nanobodies 56 calcitonin 56 TLR antagonists 56 pharmacokinetic profiles 56 XL# XL# XL# XL# 56 forodesine HCl 56 Neo Kidney Augment ™ 56 anticancer compound 56 mitogen activated ERK kinase 56 inhibit tumor 56 oral antiviral 56 EZN 56 administered subcutaneously 56 VEGF inhibitors 56 tgAAC# 56 lorvotuzumab mertansine 56 ATL/TV# 56 Excellarate 56 SparVax ™ 56 laquinimod 56 visilizumab 56 talabostat 56 evaluating tivozanib 56 SMT C# 56 ATHX 56 LymphoStat B TM 56 ADAGIO study 56 MYDICAR ® 56 Lisofylline LSF 56 bardoxolone methyl 56 deacetylase inhibitors 56 anticancer therapies 56 humanized monoclonal antibodies 56 incyclinide 56 Panzem R NCD 56 multiple ascending dose 56 TKM Ebola 56 kinase inhibitors 56 LT NS# 56 plasma kallikrein inhibitor 56 PANVAC VF 56 romidepsin 56 GFT# 56 ELACYT 56 TLR9 56 CTAP# Capsules 56 mTOR inhibition 56 EGEN 56 Aerosurf 56 Neo Kidney Augment 56 Cannabinor 56 AMPAKINE 56 vilazodone 56 SparVax TM 56 DAVANAT 56 EndoTAG TM -1 56 DB# [003] 56 antitumoral 56 phase Ib clinical 56 Phase Ib II 56 rhC1INH 56 anti CD3 monoclonal 56 antisense compounds 56 maximally tolerated dose 56 partial agonist 56 tubulin inhibitor 56 defensin mimetic antibiotic 56 Bezielle 56 Insegia 56 dexpramipexole 56 neuroprotectant 56 systemic RNAi therapeutic 56 5 HT6 antagonist 56 Saforis 56 LSI #P 56 TLR agonists 56 MT# MEDI 56 Cotara 56 registrational studies 56 Aflibercept 56 PRX# 56 Hyphanox 56 TOLAMBA 56 bosutinib 56 potent antiviral 56 VLP vaccine 56 valopicitabine 56 Virulizin ® 56 rifalazil 56 FTY# 56 Phase IIIb clinical 56 vaccine GRNVAC1 56 intravenously administered 55 Allovectin 7 ® 55 DAVANAT ® 55 PrevOnco 55 Fodosine 55 immune modulating 55 prodrug 55 vaccine adjuvant 55 antibody 55 ibudilast 55 pharmacokinetic PK study 55 teplizumab 55 HIV integrase inhibitor 55 omacetaxine 55 integrase inhibitor 55 adecatumumab 55 Ampligen R 55 potently inhibited 55 oral JAK1 55 transgenic mouse models 55 Anticalin ® 55 Solazed TM 55 rHuPH# 55 PTH analogue 55 Imprime PGG 55 Zenvia Phase III 55 oncology indications 55 tezampanel NGX# 55 inhibit KSP 55 PDX pralatrexate 55 vorinostat 55 investigational hepatitis C 55 REOLYSIN ® 55 CINOD 55 elagolix 55 anticancer 55 registrational 55 ThGRF 55 intranasal formulation 55 posaconazole 55 EpCAM 55 Anticalin 55 IL# PE#QQR 55 vitro 55 Seliciclib 55 carcinogenicity study 55 seliciclib 55 Cleviprex TM clevidipine 55 anti angiogenic agent 55 Ceflatonin 55 ALD# 55 delta isoform 55 HCV polymerase inhibitors 55 oncolytic viruses 55 XP# XP# 55 subcutaneous formulation 55 highly selective inhibitor 55 class mGluR5 inhibitor 55 LE DT 55 CYC# 55 Azedra TM 55 Onalta ™ 55 histamine dihydrochloride 55 rxRNA 55 Safinamide 55 Curaxin 55 tiapamil 55 Telintra 55 PEGylated interferon 55 OvaRex ® MAb 55 Phase #b/#a clinical 55 mu opioid receptor antagonist 55 CCR9 55 Trizytek 55 CDK inhibitors 55 rALLy trial 55 erythropoietic 55 Dapagliflozin 55 anidulafungin 55 antiviral potency 55 RNA antagonist 55 P#X# 55 BrachySil TM 55 Romidepsin 55 Ampligen ® 55 Azedra ™ 55 SILENOR TM 55 viral kinetics 55 lesinurad 55 Chimigen TM 55 geldanamycin 55 Palifosfamide 55 KL4 surfactant 55 Zemiva TM 55 mGluR5 NAM 55 Trofex ™ 55 reversible inhibitor 55 Phase #/#a trial 55 safety tolerability pharmacokinetic 55 samalizumab 55 oxidative stress inducer 55 PARP inhibitors 55 Presents Preclinical Data 55 plasma pharmacokinetics 55 partial agonists 55 molecular biomarkers 55 Pharmos proprietary 55 histone deacetylase inhibitors 55 eculizumab 55 ICA # 55 SPC# [001] 55 Fc fusion protein 55 PHX# 55 atrasentan 55 Prodarsan R 55 immunomodulatory effects 55 pivotal Phase III 55 MGd 55 Tanespimycin 55 budiodarone 55 ROTARIX 55 Cloretazine R 55 induces apoptosis 55 TBC# 55 Janus Kinase 55 LungExpress Dx TM 55 EGS# 55 PKC# 55 Oral NKTR 55 liprotamase 55 Solazed 55 UsiRNAs 55 anti CD3 55 CINTREDEKIN BESUDOTOX 55 CBLB# 55 Radezolid 55 RhuDex 55 Atu# 55 Zolinza 55 therapeutic efficacy 55 Zenvia ™ 55 hedgehog pathway 55 ALKS 55 TKM PLK1 55 polyclonal antibody 55 ARIKACE 55 safinamide 55 PEGylated interferon beta 1a 55 Trodusquemine 55 S1P antibody 55 SinuNase TM 55 prophylactic vaccine 55 monoclonal antibodies 55 Celator 55 XOMA 55 multicenter Phase II 55 #th Annual Interscience 55 lumiliximab 55 ThermoDox R 55 antisense inhibitors 55 Golimumab 55 Laquinimod 55 Cloretazine 55 MET amplification 55 INCB# [003] 55 EOquin 55 nucleoside analogues 55 Altastaph 55 Vicinium TM 55 IL #E 55 small molecule inhibitor 55 pediatric malignancies 55 sodium thiosulfate STS 55 ularitide 55 ELND-#/AZD-# 55 nucleoside analog 55 #I TM# 55 Parkinson disease levodopa induced 55 IIa trial 55 demonstrated antitumor activity 55 investigational pan BCR 55 nanoviricide drug 55 EOquin TM 55 Bortezomib 55 oxymorphone ER 55 baminercept 55 MNTX 55 potent inhibitors 55 selectively inhibits